Good morning, everyone! It’s a new week, and we hope you’re ready to tackle whatever challenges come your way. The world keeps spinning, and we’re here to help you stay informed. So grab your cup of coffee and let’s dive into some interesting updates.
According to The Wall Street Journal, there are concerns about the studies being used to determine whether the U.S. should approve an MDMA-based drug for treating post-traumatic stress disorder. Some participants reported that their thoughts of suicide worsened during or after the trials, but this information was not fully captured in the trial data. The FDA is expected to make a decision on this matter soon, which could have significant implications for the decriminalization of psychedelics.
In other news, Reuters reports that all doses of Eli Lilly’s weight loss drug Zepbound and diabetes drug Mounjaro are now available. However, these drugs are still on the FDA’s shortages list. Mounjaro has been on the list since late 2022, while Zepbound was added in April of this year. The FDA considers various criteria before removing a drug from the shortages list, such as fulfilling backorders and ensuring that the supply meets demand.
It’s important to stay informed about these developments in the pharmaceutical industry, as they can have a direct impact on patient care and treatment options. We will continue to keep you updated on any new information that arises.
If you’re interested in more exclusive stories and in-depth analysis, consider subscribing to STAT+. This subscription offers access to premium events, newsletters, and a networking platform. Stay connected and informed with award-winning journalism from industry experts like Ed Silverman, a senior writer covering the pharmaceutical industry for nearly three decades.
We hope you have a productive and successful day ahead. Remember to prioritize your well-being and stay tuned for more updates from us. Thank you for joining us, and we look forward to keeping you informed.